JPRN-jRCT2080220802未知1 期
A Phase 1, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Japanese patients with advanced solid tumors for which standard treatment does not exist or is no longer effective
- •- Must be suitable for treatment with gemcitabine
- •- Relatively good overall health other than cancer
排除标准
- •- Poor bone marrow function (not producing enough blood cells)
- •- Poor liver or kidney function
- •- Serious heart conditions
研究者
相似试验
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignanciesadvanced solid malignanciesJPRN-jRCT2080220617AstraZeneca
未知
1 期
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid MalignanciesCancer, Tumors, CarcinomaJPRN-jRCT2080220530AstraZeneca
未知
1 期
A Phase I, Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080220492AstraZeneca
Unknown
1 期
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate.EbolaPACTR201411000919191niversitaetsklinikum Tuebingen60
尚未招募
2 期
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers (BET115521)NUT Midline Carcinoma and other solid tumors10027655NL-OMON43804GlaxoSmithKline10